BackExacompta Clairefontaine S.A. Overview

Exacompta Clairefontaine S.A. EBIT

Latest ebit for ALEXA.PA: $-330M, below the sector sector average of $2.3T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$3.75M
↓ 67.5% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$327.02M
↓ 400.19% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Exacompta Clairefontaine S.A. (ALEXA.PA) FAQ

The latest EBIT for ALEXA.PA is $-330M as of June 2026. That compares with $110M in the prior-year period — down 400.2% year over year. That is below the sector sector average of $2.3T. Investors often review this figure alongside Exacompta Clairefontaine S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ALEXA.PA's EBIT moved from $110M to $-330M — a 400.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Exacompta Clairefontaine S.A.'s operating scale or balance-sheet position.

Against its sector companies, ALEXA.PA currently prints $-330M for EBIT, while the sector average sits near $2.3T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Exacompta Clairefontaine S.A.'s growth, margins, and balance sheet.

A EBIT figure of $-330M for ALEXA.PA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.3T. Explore the charts below for those layers of context.

After noting ALEXA.PA's EBIT ($-330M), review year-over-year change from $110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers